☆ 4.2 Article

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Sibylle Loibl et al.

Summary: This study investigated the effect of the antibody-drug conjugate sacituzumab govitecan (SG) on the health-related quality of life (HRQoL) in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that SG was associated with greater improvements and delayed worsening of HRQoL scores compared with other treatment options chosen by physicians.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Medicine, General & Internal

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

P. Schmid et al.

Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Economics

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Min Huang et al.

Summary: This study provides an extensive overview of the economic and humanistic burden of triple-negative breast cancer (TNBC) based on a systematic literature review. TNBC imposes a substantial economic burden on healthcare systems and societies and significantly reduces productivity and health-related quality of life for patients.

PHARMACOECONOMICS (2022)

Add to Collection

Meeting Abstract Oncology

Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States

P. A. Fasching et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Global challenges and policy solutions in breast cancer control

Dario Trapani et al.

Summary: Breast cancer is the leading cause of disability and mortality among women worldwide, with disparities in mortality rates between different countries. Investing in breast cancer control and expanding treatment capacity can improve population health. The World Health Organization has launched a global initiative to address these disparities.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Article Oncology

HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis

Amin Haiderali et al.

Journal of the National Comprehensive Cancer Network (2022)

Add to Collection

Article Multidisciplinary Sciences

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany

Florian Schwarz et al.

Summary: This study evaluated the cost-effectiveness factors of talazoparib for patients with a germline breast-cancer-gene (brca) mutation and locally advanced or metastasized breast cancer in the German healthcare system. The findings suggest that talazoparib is not cost-effective at current pricing.

PLOS ONE (2022)

Add to Collection

Article Oncology

Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021

Daniel Tobias Michaeli et al.

Summary: The study found that new cancer drugs significantly reduce the risk of death and tumor progression, but have limited impact on extending patient survival. Drugs approved initially were more likely to receive accelerated approval and were supported by single-arm trials compared to indication extensions.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer.

Christie Zettler et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

J. Cortes et al.

Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States

Yitian Lang et al.

Summary: The cost-effectiveness analysis suggests that trastuzumab deruxtecan is unlikely to be a preferred option for patients with HER2-low breast cancer at the current price threshold of $150,000/QALY from a US payer perspective.

BREAST CANCER-TARGETS AND THERAPY (2022)

Add to Collection

Article Oncology

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C. E. Geyer et al.

Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Immunology

Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

Min Huang et al.

Summary: This study evaluated the cost-effectiveness of pembrolizumab/chemotherapy combinations as first-line treatment for previously untreated metastatic triple-negative breast cancer patients with PD-L1 combined positive score >= 10. The results showed that pembrolizumab/chemotherapy had advantages over chemotherapy alone in terms of quality-adjusted life-year gains and incremental cost-effectiveness ratio.

IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Current and future burden of breast cancer: Global statistics for 2020 and 2040

Melina Arnold et al.

Summary: Breast cancer is the most commonly diagnosed cancer worldwide, with over 2.3 million new cases and 685,000 deaths in 2020. There is significant geographic variation in incidence rates, with lower rates in some Asian and African countries and higher rates in countries like Australia, New Zealand, Northern America, and parts of Europe. Mortality rates show less variation, but transitioning countries still bear a disproportionate burden of breast cancer deaths. By 2040, the burden of breast cancer is predicted to increase further due to population growth and ageing. Global efforts are needed to address this growing burden, especially in transitioning countries where incidence rates are rising rapidly and mortality rates remain high.

BREAST (2022)

Add to Collection

Review Oncology

Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?

Eleonora Nicolo et al.

Summary: The introduction of antibody-drug conjugates (ADCs) has greatly changed the therapeutic landscape for breast cancer patients. Besides human epidermal growth factor receptor 2 (HER2), any surface antigen with differential expression between tumor and normal cells could be targeted with ADCs. Exploration of new targets is important to increase the number of patients who can benefit from ADCs.

CANCER JOURNAL (2022)

Add to Collection

Review Oncology

Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments

Dario Trapani et al.

Summary: This paper reviews the challenges in conducting HTA for cancer medicines, including the uncertainties of clinical trial designs and safety-efficacy data. The lack of robust data could potentially result in misinformed resource allocation for cancer medicines.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer

Christine Brezden-Masley et al.

Summary: The study analyzed data of Canadian women with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. The costs associated with metastatic breast cancer were found to be significantly higher with inpatient hospital services representing a large portion of total costs. Low rates of endocrine treatment captured by the publicly funded system suggest guideline non-adherence or potential out-of-pocket drug costs for patients in Ontario.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan

Yugo Chisaki et al.

Summary: The study evaluated the cost effectiveness of atezolizumab plus nab-paclitaxel therapy compared with nab-paclitaxel monotherapy for PD-L1-positive TNBC in a Japanese setting. Results showed that AnP treatment had longer QALYs but higher total costs than nP treatment, indicating that AnP was not cost effective in this context.

CLINICAL DRUG INVESTIGATION (2021)

Add to Collection

Article Health Care Sciences & Services

Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

Karen E. Skinner et al.

Summary: This study aimed to evaluate the monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. The majority of costs were found to be attributable to hospitalization and emergency department services, suggesting the need for effective interventions to reduce the utilization of costly services.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis

Xiaoyan Liu et al.

Summary: The study assessed the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health sector. While adding atezolizumab to nab-paclitaxel showed significant improvement in survival time for PD-L1-positive group, it was not a cost-effective strategy compared to nab-paclitaxel monotherapy for Chinese patients with advanced or metastatic TNBC in the context of current economic situation in China.

FRONTIERS IN PUBLIC HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles et al.

Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Antonio Olry de Labry Lima et al.

Summary: The study analyzed the cost-utility ratio and budgetary impact of talazoparib treatment for breast cancer patients, showing that while talazoparib was more effective, its cost was higher, requiring a price reduction to reach cost-utility thresholds.

BREAST (2021)

Add to Collection

Editorial Material Oncology

The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level

Jacopo Giuliani et al.

Summary: The analysis evaluated the pharmacological costs of atezolizumab as first-line treatment in triple negative metastatic breast cancer, indicating potential cost-effectiveness only in PD-L1-positive population.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

Add to Collection

Article Oncology

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis

Xiuhua Weng et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Health Care Sciences & Services

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

Lee Cheng Phua et al.

BMC HEALTH SERVICES RESEARCH (2020)

Add to Collection

Article Immunology

Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer

Jiahao Li et al.

IMMUNOTHERAPY (2020)

Add to Collection

Editorial Material Health Care Sciences & Services

The six Delta platform for outcome-based contracting for pharmaceuticals

Nimer S. Alkhatib et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

Add to Collection

Article Oncology

Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype

Mariana Brandao et al.

ESMO OPEN (2020)

Add to Collection

Article Oncology

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

J. K. Litton et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Oncology

Triple-negative breast cancer molecular subtyping and treatment progress

Li Yin et al.

BREAST CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer

Bin Wu et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer

Shota Saito et al.

PERSONALIZED MEDICINE (2019)

Add to Collection

Article Economics

PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE

C. McCrea et al.

VALUE IN HEALTH (2019)

Add to Collection

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

ESMO-Magnitude of Clinical Benefit Scale version 1.1

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Meeting Abstract Economics

CANCER ASSOCIATED MEDICAL SPENDING: US NATIONAL DATA BETWEEN 2000 AND 2013

J. Zhuo et al.

VALUE IN HEALTH (2016)

Add to Collection

Review Multidisciplinary Sciences

Economic Benefits of Investing in Women's Health: A Systematic Review

Kristine Husoy Onarheim et al.

PLOS ONE (2016)

Add to Collection

Article Oncology

Triple negative breast cancer - prognostic factors and survival

Tanja Ovcaricek et al.

RADIOLOGY AND ONCOLOGY (2011)

Add to Collection

Article Oncology

The epidemiology of triple-negative breast cancer, including race

Katrina F. Trivers et al.

CANCER CAUSES & CONTROL (2009)

Add to Collection

Article Oncology

Assessing the economic burden of breast cancer in a US managed care population

John J. Barron et al.

BREAST CANCER RESEARCH AND TREATMENT (2008)

Add to Collection

Article Oncology

Triple-negative breast cancer: Clinical features and patterns of recurrence

Rebecca Dent et al.

CLINICAL CANCER RESEARCH (2007)

Add to Collection

Article Oncology

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.